We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Type Linked to Risk of COVID-19 Infection Severity

By LabMedica International staff writers
Posted on 04 Jan 2021
Identification of risk factors for contracting and developing serious illness following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is of paramount interest. More...
Development of COVID-19 is associated with age, sex, and comorbidities, such as cardiovascular diseases, although severe disease is not limited to these risk groups.

Blood group A and B glycosyltransferases also affect glycosylation in a large number of cell types, including epithelial cells in the respiratory tract and shed viral particles. A, B, and AB individuals are also at increased risk for thrombosis and cardiovascular diseases, which are important comorbidities among hospitalized COVID-19 patients, possibly mediated by glycosylation of proteins involved in hemostasis.

Clinical Immunologists at the Odense University Hospital (Odense, Denmark) and their colleagues analyzed data in a retrospective cohort study, of over 840,000 individuals in Denmark who underwent testing by polymerase chain reaction for SARS-CoV-2 between February 27 and July 30, 2020. Most of those tested (56%) had available ABO and RhD blood group information. The team also used ABO and RhD data of 2,204,742 individuals not tested for SARS-CoV-2 as a reference. This corresponded to approximately 38% of the entire Danish population.

The scientists reported that of the 473,654 tested individuals who had a known blood group, 7,422 were positive for SARS-CoV-2 and 466,232 were negative. The positive and negative groups had similar proportions of men (32.9% versus 32%) and similar median ages (52 years versus 50 years). Among patients with SARS-CoV-2, considerably fewer (38.4%) had blood type O than other tested blood types. When excluding blood type O, they observed no significant differences among patients with blood types A, B and AB. They also observed no difference in the RhD group between positive cases and the reference population. The investigators reported relative risk (RR) for contracting SARS-CoV-2 of 0.87 for blood type O, 1.09 for blood type A, 1.06 for blood type B and 1.15 for blood type AB.

Torben Barington, MD, a Professor of Medicine and the senior author of the study, said, “ABO blood groups are increasingly recognized to influence susceptibility to certain viruses, including SARS-CoV-1 and norovirus. A, B and AB individuals are also at increased risk for thrombosis and cardiovascular diseases, which are important comorbidities among hospitalized COVID-19 patients, possibly mediated by glycosylation of proteins involved in hemostasis.” The study was originally published on October 14, 2020 in the journal Blood Advances.

Related Links:
Odense University Hospital


New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Portable Electronic Pipette
Mini 96
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: Private equity firms Blackstone and TPG have joined forces to acquire Hologic in a major healthcare deal (Photo courtesy of Hologic)

Hologic to be Acquired by Blackstone and TPG

Hologic (Marlborough, MA, USA) has entered into a definitive agreement to be acquired by funds managed by Blackstone (New York, NY, USA) and TPG (San Francisco, CA, USA) in a transaction valued at up to... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.